SPTSSB (serine palmitoyltransferase small subunit B) is a regulatory component of the serine palmitoyltransferase (SPT) complex that catalyzes the initial and rate-limiting step of sphingolipid biosynthesis by condensing L-serine with activated acyl-CoA to form long-chain bases 1. Within the multi-subunit SPT complex, SPTSSB stimulates catalytic activity and determines substrate specificity, with different SPTSSB-containing complexes showing preferences for distinct acyl-CoA chain lengths; the SPTLC1-SPTLC2-SPTSSB complex preferentially uses C18-CoA, while SPTLC1-SPTLC3-SPTSSB displays broader substrate utilization 1. SPTSSB plays a critical role in regulating sphingolipid long-chain base diversity in tissues including skin and urinary bladder 23. Dysregulation of SPTSSB has been implicated in multiple disease states: a mutation increasing C20 long-chain base production causes neurodegeneration with axonal damage 4; elevated SPTSSB expression associates with increased plasma ceramides and Parkinson's disease risk 5; and SPTSSB appears as a predictive biomarker for intervertebral disc degeneration 6 and Alzheimer's disease 7. SPTSSB represents a viable therapeutic target, with covalent xanthone inhibitors successfully reducing sphingolipid levels in vitro and in vivo 8, suggesting therapeutic potential in diseases involving pathological sphingosine-1-phosphate signaling.